Mirum and Kodiak Sciences share study results
Mirum 與 Kodiak Sciences 分享研究結果
更新於: 2026年9月28日 上午01:45
On September 28, 2026, the biotechnology sector saw significant updates from two major companies: Mirum Pharmaceuticals and Kodiak Sciences.
2026年9月28日，生物技術產業出現了來自兩家大型企業的重要更新：Mirum Pharmaceuticals與Kodiak Sciences。
While their announcements occurred on the same day, it is crucial to note that they are not collaborating.
雖然它們的公告發生在同一天，但必須注意的是，兩者並未合作。
These are entirely separate corporate updates involving distinct clinical trials and therapeutic focuses.
這些是涉及不同臨床試驗與治療重點的完全獨立企業更新。
Mirum Pharmaceuticals hosted an investor call to share positive topline results from their Phase 3 AZURE-1 study of brelovitug, which targets chronic hepatitis delta virus (HDV).
Mirum Pharmaceuticals舉辦了一場投資人電話會議，分享其針對慢性丁型肝炎病毒（HDV）的brelovitug藥物在第三期AZURE-1研究中的正面初步結果。
Meanwhile, Kodiak Sciences held a webcast to report findings from their DAYBREAK pivotal Phase 3 study.
與此同時，Kodiak Sciences舉辦了一場網路廣播，報告其DAYBREAK樞紐性第三期研究的發現。
By looking at these companies, we see a clear divide: Mirum remains focused on rare diseases, while Kodiak Sciences concentrates on retinal health.
透過觀察這兩家公司，我們可以發現明確的區別：Mirum持續專注於罕見疾病，而Kodiak Sciences則聚焦於視網膜健康。
Understanding that these are independent milestones helps investors and researchers avoid confusion between different drugs, study goals, and market strategies.
了解這些是獨立的里程碑，有助於投資人與研究人員避免混淆不同的藥物、研究目標與市場策略。
